1. Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse
- Author
-
Shapiro, Roman M., Birch, Grace C., Hu, Guangan, Cadavid, Juliana Vergara, Nikiforow, Sarah, Baginska, Joanna, Ali, Alaa K., Tarannum, Mubin, Sheffer, Michal, Abdulhamid, Yasmin Z., Rambaldi, Benedetta, Arihara, Yohei, Reynolds, Carol, Halpern, Max S., Rodig, Scott J., Cullen, Nicole, Wolff, Jacquelyn O., Pfaff, Kathleen L., Lane, Andrew A., Lindsley, R. Coleman, Cutler, Corey S., Antin, Joseph H., Ho, Vincent T., Koreth, John, Gooptu, Mahasweta, Kim, Haesook T., Malmberg, Karl-Johan, Wu, Catherine J., Chen, Jianzhu, Soiffer, Robert J., Ritz, Jerome, and Romee, Rizwan
- Subjects
Diseases -- Relapse ,Killer cells -- Physiological aspects -- Usage -- Health aspects ,Hematopoietic stem cells -- Transplantation ,Health care industry - Abstract
BACKGROUND. Responses to conventional donor lymphocyte infusion for postallogeneic hematopoietic cell transplantation (HCT) relapse are typically poor. Natural killer (NK) cell-based therapy is a promising modality to treat post-HCT relapse. METHODS. We initiated this ongoing phase I trial of adoptively transferred cytokine-induced memory-like (CIML) NK cells in patients with myeloid malignancies who relapsed after haploidentical HCT. All patients received a donor-derived NK cell dose of 5 to 10 million cells/kg after lymphodepleting chemotherapy, followed by systemic IL-2 for 7 doses. Highresolution profiling with mass cytometry and single-cell RNA sequencing characterized the expanding and persistent NK cell subpopulations in a longitudinal manner after infusion. RESULTS. In the first 6 enrolled patients on the trial, infusion of CIML NK cells led to a rapid 10- to 50-fold in vivo expansion that was sustained over months. The infusion was well tolerated, with fever and pancytopenia as the most common adverse events. Expansion of NK cells was distinct from IL-2 effects on endogenous post-HCT NK cells, and not dependent on CMV viremia. Immunophenotypic and transcriptional profiling revealed a dynamic evolution of the activated CIML NK cell phenotype, superimposed on the natural variation in donor NK cell repertoires. CONCLUSION. Given their rapid expansion and long-term persistence in an immune-compatible environment, CIML NK cells serve as a promising platform for the treatment of posttransplant relapse of myeloid disease. Further characterization of their unique in vivo biology and interaction with both T cells and tumor targets will lead to improvements in cell-based immunotherapies. TRIAL REGISTRATION. ClinicalTrials.gov NCT04024761. FUNDING. Dunkin' Donuts, NIH/National Cancer Institute, and the Leukemia and Lymphoma Society., Introduction Relapse of acute myeloid leukemia (AML) occurs in up to 50% of patients after allogeneic hematopoietic stem cell transplant (HCT) and heralds an extremely poor prognosis (1). In several [...]
- Published
- 2022
- Full Text
- View/download PDF